Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 49 | ECE2017 | Next issue

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

Card image cap
20-23 May 2017, Lisbon, Portugal Further information

Guided Posters

Pituitary & endocrine Tumours

ea0049gp185 | Pituitary & endocrine Tumours | ECE2017

Localization of benign insulinomas using glucagon-like peptide-1 receptor (GLP1-R) SPECT/CT and PET/CT and MRI in a prospective clinical study

Antwi Kwadwo , Fani Melpomeni , Heye Tobias , Nicolas Guillaume , Merkle Elmar , Reubi Jean Claude , Gloor Beat , Wild Damian , Christ Emanuel

Purpose: We aim at prospectively comparing the detection rate of GLP1-R PET/CT vs GLP1-R SPECT/CT vs standardized contrast enhanced 3T-MRI in patients with suspected insulinoma.Methods: 40 patients with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled.3T-MRI was performed. Afterwards patients received SPECT/CT after injection of 111In-DOTA-exendin-4 and PET/CT after injection of <sup...

ea0049gp186 | Pituitary &amp; endocrine Tumours | ECE2017

24 hour urinary 5-hydroxyindoleacetic acid (5-HIAA) doubling-time (DT) is associated with disease-specific mortality (DSM) and progression-free survival (PFS) in patients with neuroendocrine tumors (NETs)

Tirosh Amit , Nilubol Naris , Patel Dhaval , Kebebew Electron

Background: Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies. The aim of the current analysis was to determine whether biomarker DT has any prognostic utility in patients with NETs.Methods: Patients with NETs (n=184) were enrolled in a prospective study with comprehensive biochemical analysis. The current analysis included subjects with increasing 5-HIAA levels in at least two consecutive measure...

ea0049gp187 | Pituitary &amp; endocrine Tumours | ECE2017

Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing’s disease (CAPACITY)

Pivonello Rosario , Kadioglu Pritam , Bex Marie , Devia Deyanira Gonzalez , Boguszewski Cesar , Yavuz Dilek Gogas , Patino Heather , Campigotto Federico , Pedroncelli Alberto , Fleseriu Maria , Biller Beverly M K , Feelders Richard

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushing’s disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

ea0049gp188 | Pituitary &amp; endocrine Tumours | ECE2017

Vertebral fractures are prevalent among patients with acromegaly in spite of normal bone mineral density reflecting overall duration of disease regardless of biochemical control or cure

Stojanovic Marko , Miljic Dragana , Pekic Sandra , Doknic Mirjana , Djurovic Marina Nikolic , Jemuovic Zvezdana , Popovic Vera , Petakov Milan

Introduction: Skeletal complications of acromegaly are among its most persistent and invalidating impacts. Dual-X-ray absorptiometry (DXA) alone might be insufficient or even misleading for bone health assessment in acromegaly.Patients and methods: Patients with acromegaly (N=170) were classified as active (N=104), operatively cured (N=34) or medically controlled (N=32). 57 males and 113 females were included, 52.8 (22...

ea0049gp189 | Pituitary &amp; endocrine Tumours | ECE2017

Evaluation of pituitary toxicity after radiotherapy for cerebral chondrosarcomas in adult patients

Laroche Suzanne , Feuvret Loic , Beauchet Alain , Dendale Remi , Chanson Philippe , Bruckert Eric , Jublanc Christel

Pituitary dysfunction can be a consequence of cranial radiotherapy. It usually occurs years after the treatment. However little is known on risk factors for pituitary dysfunction. The object of this study was to evaluate radiation induced pituitary toxicity of proton beam therapy in a cohort of adult chondrosarcoma patients.The files of 113 patients were reviewed. Mean age at the beginning of radiotherapy was 43 years old (18–76). Mean dose delivere...

ea0049gp190 | Pituitary &amp; endocrine Tumours | ECE2017

Safety of long-term growth hormone (GH) treatment in adults with GH deficiency (GHD): an analysis from the NordiNet® International Outcome Study

Jorgensen Jens Otto , Popovic-Brkic Vera , Pournara Effie , Pedersen Birgitte , Chudecka Anita , Strasburger Christian

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...

ea0049gp191 | Pituitary &amp; endocrine Tumours | ECE2017

GH and IGF-1 levels at 12 weeks predict long-term responses to lanreotide Autogel in treatment-naïve acromegalic patients: post-hoc analyses from the PRIMARYS study

Caron Philippe , Petersenn Stephan , Houchard Aude , Sert Caroline , Bevan John S

Background: In PRIMARYS, lanreotide Autogel (LAN) 120 mg/28 days reduced tumour volume (TV), and GH/IGF-1 levels in patients with GH-secreting macroadenomas. In post-hoc analyses, we investigated predictive factors for treatment responses.Methods: PRIMARYS, a 48-week, international, open-label study, involved 90 treatment-naïve patients with GH-secreting macroadenomas receiving LAN. Factors predictive for hormonal control (HC; GH ≤2.5...

ea0049gp192 | Pituitary &amp; endocrine Tumours | ECE2017

Long-term treatment with pegvisomant (Somavert®): Observations from 2090 acromegaly patients followed in ACROSTUDY

vanderLely Aart Jan , Biller Beverly , Brue Thierry , Buchfelder Michael , Ghigo Ezio , Pan kaijie , Jonsson Peter , Lavenberg Joanne , Strasburger Christian J. , Webb Susan , Camacho-Hubner Cecilia , Hey-Hadavi Judith

Introduction: Pegvisomant (PEGV) is approved for the treatment of acromegaly since 2003. This is the second interim analysis of data from ACROSTUDY, with the majority of patients treated for at least five years (yrs).Methods/design: ACROSTUDY is an international, open-label, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of PEGV. Patients were enrolled in the study on an ongoing basis.<...

ea0049gp193 | Pituitary &amp; endocrine Tumours | ECE2017

Amenorrhea without vasomotor symptoms in women over 40: A sign of pathological hyperprolactinemia?

Ilovayskaya Irena , Dreval Alexader , Krivosheeva Yulia

Background: Hyperprolactinemia is often seen in women of reproductive age (20–35 years), most often due to microprolactinoma. However, prolactinomas do occur in older women.Objective: To analyze clinical features of hyperprolactinemia in women >40 yearsMaterial and methods: Clinical and biochemical data of 185 women with pathological hyperprolactinemia were analyzed.Results: Seventy (37.8%) patients ...

ea0049gp194 | Pituitary &amp; endocrine Tumours | ECE2017

Serotonin, ATRX and DAXX as differential diagnostic markers of neuroendocrine tumours (NETs) in the sellar region. An immunohistochemical study in a large series of pituitary adenomas and in a non-pituitary NET

Casar-Borota Olivera , Botling Johan , Granberg Dan , Wikstrom Johan , Ponten Fredrik , Trouillas Jacqueline

We present a case of a patient with a locally invasive, serotonin- and ACTH-reactive tumour in the sellar region, filling the sphenoid sinus and expanding into the epipharynx. Clinical examination completed by 68-Gallium-DOTA-TOC PET revealed tracer uptake in the sellar tumour as well as in a 7 mm lesion in the pancreatic tail. A differential diagnosis between silent corticotroph adenoma and another primary or secondary neuroendocrine tumour (NET) with ACTH-expression was diff...

ea0049gp195 | Pituitary &amp; endocrine Tumours | ECE2017

Long-term follow-up of a family with a large AIP gene deletion: variable phenotypes and challenges in the management

Marques Pedro , Dang Mary , Ogilvie Arla , Storr Helen , Powell Michael , Grieve Joan , Evason Jane , Kumar Ajith , Korbonits Marta

Introduction: Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations are responsible for 15–30% of familial isolated pituitary adenomas (FIPA). We report a 4-generation FIPA kindred with a heterozygous AIP gene deletion in exon 2, highlighting the benefits of genetic screening and management challenges in affected subjects and asymptomatic carriers.Patients: A 45y woman died of a spinal ependymoma (obligate carrier)...

ea0049gp196 | Pituitary &amp; endocrine Tumours | ECE2017

Diagnosis of acromegaly: Sex and BMI are the major determinants of growth hormone suppression during oral glucose tolerance test (OGTT)

Schilbach Katharina , Nicolay Shiva Sophia , Haenelt Michael , Lechner Andreas , Gar Christina , Schopohl Jochen , Stormann Sylvere , Schwaiger Rita , Bidlingmaier Martin

GH suppression during OGTT is the gold-standard test in diagnosis and monitoring of acromegaly. However, discrepancies between GH nadir and IGF-I have been described and have triggered search for factors modifying the extent of GH suppression. Cut-offs at 1.0 or 0.4 ng/ml are currently recommended with modern, highly sensitive GH assays. To establish assay specific GH nadir cutoffs for the 22kD GH specific IDS-iSYS assay, we examined 381 subjects (319 females, 62 males) with n...